Novartis (NVS) and The Medicines Co. (MDCO) merger information including expected completion date and offer price are displayed in the deal information table below.
This deal was successfully consummated on January 6, 2020
| Merger Details | Value |
|---|---|
| Acquisition Target Stock Name | The Medicines Co. |
| Acquisition Target Stock Ticker | MDCO |
| Acquirer Stock Name | Novartis |
| Announcement Date | November 24, 2019 |
| Tender Offer Closing Date | January 3, 2020 |
| Offer Price | $85.00 |
| Payment Method | All Cash Deal, Tender Offer |
| Actual Completion Date | January 6, 2020 |
The major The Medicines Co. (MDCO) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the Novartis (NVS) takeover of The Medicines Co. (MDCO) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on the The Medicines Co. (MDCO) buyout, follow this link The Medicines Co. (MDCO). Change the ticker symbol as required to access news and acquisition details of additional merger stocks. The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated MDCO news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deals by simply entering a ticker symbol into the search box in the menu bar above or click on an acquisition target stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
The Medicines Co. (NASDAQ: MDCO) Merger - Acquisition News and Events
The Medicines Co. Company Profile
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
